• Led the strategic planning and execution of translational studies to support early phase clinical trials exploring the potential of the macrophage targeting agent, eganelisib in combination with standard of care in metastatic triple negative breast cancer and metastatic urothelial carcinoma• Coordinated activities among networks of scientists, collaborators, external CROs and bioinformatic consultants to meet time-driven goals• Evaluated and prioritized preclinical and clinical collaborations to support the clinical development strategy as a member of the clinical-translational-preclinical (CTP) leadership team• Leveraged biomarker analysis to support the use of eganelisib in PD-L1 negative cancer • Proposed and executed company publication strategy as a member of the product leadership team• Generated and presented key scientific findings at medical conferences as an invited speaker and contributing author to poster presentations• Provided subject matter expertise for regulatory interactions and documents including protocols, investigator brochures, FDA briefing books and regulatory responses

• Operationalized Translational Medicine function for Phase 1 and Phase 2 clinical trials which included setting the strategy, developing a budget and contract oversight• Evaluated investigator sponsored trial (IST) proposals for fit within clinical development strategy• Collaborated with clinical pharmacology to evaluate pharmacokinetic-pharmacodynamic relationships (PK-PD studies)• Managed CROs, assuring data quality and assay optimization for Digital Spatial Profiling, RNAseq, Flow Cytometry, Luminex, Immunohistochemistry, Multiomyx• Managed a team of bioinformatics consultants developing a data analysis platform• Facilitated clinical operation activities for study start up including lab manual setup, site initiation visits training materials, protocol writing, and implementation of a sample tracking process

As a member of a highly integrated team of scientists, my primary responsibility was to support early discovery pipeline expansion efforts in oncology. I assisted in the evaluation of potential in-licensing opportunities as well as internal drug discovery programs by conducting relevant cell biology assays under strict timelines. As a lead senior scientist, I contributed to the initiation, execution, and evaluation of early discovery programs. I managed direct and indirect reports, led cross functional team meetings and presented my work in a variety of settings including conferences, team meetings and company wide program reviews.

As a scientist in the Therapeutic Discovery Group at Amgen, I worked in a highly collaborative, team-based environment to facilitate early stage target validation of small molecule programs in Oncology. I also performed assay development and cell line generation to support and enable early stage drug discovery efforts in Neuroscience and Oncology.

As a post doctoral fellow in Wade Harper's lab, I utilized genomic and proteomic approaches to identify novel regulators of the DNA damage response. I performed a genome-wide RNAi screen for camptothecin sensitivity/resistance which led to the identification of a novel mammalian MMS22L-NKFBIL2 complex required for genomic stability.

As a post doctoral research associate in John Sedivy's lab, I studied the role of c-Myc in the regulation of transcription through promoter escape.

Generated reagents and performed plate based assays to support early stage drug discovery efforts in Oncology.

Trained and certified quality control laboratories in analytical methods at Pfizer branches including Groton, CT, Sandwich, England, and San Juan, Puerto Rico.

Assayed drug potency and purity using high-performance liquid chromatography in compliance with good manufacturing practices (GMP).